AR033444A1 - SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT - Google Patents

SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT

Info

Publication number
AR033444A1
AR033444A1 ARP020101068A ARP020101068A AR033444A1 AR 033444 A1 AR033444 A1 AR 033444A1 AR P020101068 A ARP020101068 A AR P020101068A AR P020101068 A ARP020101068 A AR P020101068A AR 033444 A1 AR033444 A1 AR 033444A1
Authority
AR
Argentina
Prior art keywords
dosage form
nicotine
nicotine compound
active
active nicotine
Prior art date
Application number
ARP020101068A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR033444A1 publication Critical patent/AR033444A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Abstract

Una forma solida de dosificacion oral, util para la administracion oral de un compuesto activo de nicotina a través de la mucosa que comprende: a) una matriz vítrea que comprende por lo menos un azucar - alcohol sustancialmente no higroscopico capaz de formar una estructura vítrea,y b) un compuesto activo de nicotina, en una cantidad eficaz para reducir el ansia de nicotina. El azucar - alcohol puede comprender una mezcla de 1,6-GPS(6-O-alfa-D-glucopiranosil-D-sorbitol) y 1,1-GMP(1-O-alfa-D-glucopiranosil-D-manitol) en una relacion ponderal de aproximadamente 99:1 a aproximadamente 1:99. El compuesto activo de nicotina se puede seleccionar de nicotina, derivados de nicotina, y combinaciones de los mismos. Uso de un compuesto activo de nicotina para preparar la forma solida de dosificacion oral descripta en un método de aplicacion para reducir el ansia de nicotina y/o el uso del tabaco que comprende administrar oralmente la forma de dosificacion a una persona que necesite reduccion del ansia de nicotina o el uso de tabaco. Dicha forma de dosificacion puede proporcionar una concentracion de compuesto activo de nicotina en el plasma sanguíneo de por lo menos aproximadamente 6 ng/ml después de iniciar la administracion oral de la forma de dosificacionA solid oral dosage form, useful for oral administration of an active nicotine compound through the mucosa comprising: a) a vitreous matrix comprising at least one substantially non-hygroscopic sugar-alcohol capable of forming a vitreous structure, and b) an active nicotine compound, in an amount effective to reduce nicotine craving. The sugar-alcohol may comprise a mixture of 1,6-GPS (6-O-alpha-D-glucopyranosyl-D-sorbitol) and 1,1-GMP (1-O-alpha-D-glucopyranosyl-D-mannitol) in a weight ratio of about 99: 1 to about 1:99. The active nicotine compound can be selected from nicotine, nicotine derivatives, and combinations thereof. Use of an active nicotine compound to prepare the solid oral dosage form described in an application method to reduce nicotine craving and / or the use of tobacco comprising orally administering the dosage form to a person in need of craving reduction of nicotine or tobacco use. Said dosage form may provide a concentration of active nicotine compound in the blood plasma of at least about 6 ng / ml after starting oral administration of the dosage form.

ARP020101068A 2001-03-26 2002-03-22 SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT AR033444A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27860601P 2001-03-26 2001-03-26

Publications (1)

Publication Number Publication Date
AR033444A1 true AR033444A1 (en) 2003-12-17

Family

ID=23065632

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101068A AR033444A1 (en) 2001-03-26 2002-03-22 SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT

Country Status (11)

Country Link
EP (1) EP1372392A4 (en)
JP (1) JP2004525928A (en)
CN (2) CN101301275A (en)
AR (1) AR033444A1 (en)
AU (1) AU2002252470B2 (en)
BR (1) BR0208382A (en)
CA (1) CA2440713A1 (en)
MX (1) MXPA03008762A (en)
NZ (1) NZ528167A (en)
PL (1) PL364621A1 (en)
WO (1) WO2002076211A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
ES2654062T3 (en) * 2003-07-24 2018-02-12 Glaxosmithkline Llc Oral Dissolution Films
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
EP1691631A4 (en) 2003-11-07 2012-09-05 Us Smokeless Tobacco Co Tobacco compositions
PL1786272T3 (en) * 2004-08-11 2015-02-27 Intercontinental Great Brands Llc Warming compositions and delivery systems therefor
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080131508A1 (en) * 2006-12-01 2008-06-05 Cephalon, Inc Oral transmucosal nicotine dosage form
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
KR101122469B1 (en) 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 Methods and compositions for reduction of side effects of therapeutic treatments
DE102008012015A1 (en) * 2008-03-01 2009-09-10 Südzucker AG Mannheim/Ochsenfurt Improved isomalt-containing compresses and processes for their preparation
EP2536409A4 (en) * 2010-02-18 2013-07-17 Jatin Vasant Thakkar Nicotine-containing soft gelatin pastilles
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
UA112974C2 (en) * 2010-09-16 2016-11-25 Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид NICOTINE COMPOSITION (OPTIONS)
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9044035B2 (en) * 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
AR096223A1 (en) * 2013-05-10 2015-12-16 Glaxosmithkline Llc NICOTINE PILL FOR ORAL ADMINISTRATION
CN104132895B (en) * 2014-07-08 2017-08-25 国家烟草质量监督检验中心 The buffer system of total alkaloid tobacco and tobacco product is determined suitable for continuous flow method
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
SE541358C2 (en) * 2017-05-30 2019-08-13 Enorama Pharma Ab Nicotine-containing chewing gum compositions
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
CN115003281A (en) * 2020-01-15 2022-09-02 麦克内尔股份公司 Pastille
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
DE19536394A1 (en) * 1995-09-29 1997-04-03 Basf Ag Solid pharmaceutical forms, obtainable by extrusion of a polymer-active substance melt containing isomalt
DE19639342C2 (en) * 1996-09-25 1998-07-16 Suedzucker Ag Chewing gum containing a sweetener
US6322806B1 (en) * 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center

Also Published As

Publication number Publication date
WO2002076211A1 (en) 2002-10-03
CN101301275A (en) 2008-11-12
JP2004525928A (en) 2004-08-26
CN1553771A (en) 2004-12-08
MXPA03008762A (en) 2004-02-18
BR0208382A (en) 2004-06-15
AU2002252470B2 (en) 2008-05-22
EP1372392A4 (en) 2004-06-23
PL364621A1 (en) 2004-12-13
NZ528167A (en) 2005-04-29
EP1372392A1 (en) 2004-01-02
CA2440713A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
AR033444A1 (en) SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT
EP0735859B1 (en) A pharmaceutical composition for the intranasal administration of hydroxocobalamin
NO993520D0 (en) Dosage forms and methods for improving erectile dysfunction
AR037592A1 (en) PHARMACEUTICAL FORMULATIONS OF 5,7,14-TRIAZATETRACICLO (10.3.1.02,11.04,9) -HEXADECA-2 (11), 3,5,7,9-PENTAENO
AR059324A2 (en) A solid form of oral dosing
CO5560558A2 (en) USE OF A CELECOXIB COMPOSITION FOR PAIN RELIEF FAST
DK1257254T3 (en) Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
CO5261582A1 (en) VALDECOXIB COMPOSITIONS
CO5680109A1 (en) COMPOUNDS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION
ES2096781T3 (en) COMPOSITIONS OF CONTROLLED RELEASE OXICODONS.
ECSP055606A (en) PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION BY ORAL OF ANALGESIC MEDICINES
AR048431A1 (en) GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
CL2009001899A1 (en) Pharmaceutical composition comprising: i) an at1 receptor antagonist or a salt, ii) an insulin sensitizer or a salt and iii) a pharmaceutically acceptable carrier; use for the prevention, delay of progress or treatment of hypertension, diabetes, among others (div. sol. 2034-01).
DE69027216D1 (en) TRANSMUCOSAL DOSAGE FORM
AR033688A1 (en) RECONSTITUABLE PARENTERAL COMPOSITION
CO5280073A1 (en) COMPOSITIONS
DE60024491D1 (en) FAST-ACTIVE, FREEZER-DRY, ORAL, PHARMACEUTICAL FORMULATION FOR TREATMENT OF MIGRAINE
ES2171440T3 (en) SOLID COMPOSITION MUCOADHESIVA, THERAPEUTICS OR HYGIENIC, FOR ADMINISTRATION BY APPLICATION ON THE MUCOSA ORAL OR NASAL.
ATE388687T1 (en) MEDICINAL ADMINISTRATION OF NICOTINE IN THE FORM OF CHEWING GUM
DE50203456D1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
AR015744A1 (en) USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY
ES2175663T3 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS.
RU2007133435A (en) METHOD OF COMBINED TREATMENT AND APPLICABLE FOR THIS COMBINATION OF MEDICINES
BRPI0412430A (en) zot and zonulin receptor agonist polypeptide
AR042153A1 (en) USE OF COMPOUNDS 2,5- DIHYDROXIBENCENOSULFONICOS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FB Suspension of granting procedure